Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$3.24 USD
-0.07 (-2.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KYTX 3.24 -0.07(-2.11%)
Will KYTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYTX
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise | ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
Kyverna Therapeutics appoints Marc Grasso as CFO
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer | KYTX Stock News
Kyverna Therapeutics names Marc Grasso, M.D., as CFO